SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
8
0
0
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
25.0%
2 terminated out of 8 trials
60.0%
-26.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
NAC for Attenuation of COVID-19 Symptomatology
Cardiovascular Implications of COVID-19
Observational Study of COVID-19 Treatment Efficacy
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
A Study of ResCure™ to Treat COVID-19 Infection
Efficacy of Nicotine in Preventing COVID-19 Infection